Wei‐Xiong Xia

1.7k total citations
65 papers, 912 citations indexed

About

Wei‐Xiong Xia is a scholar working on Otorhinolaryngology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Wei‐Xiong Xia has authored 65 papers receiving a total of 912 indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Otorhinolaryngology, 41 papers in Oncology and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Wei‐Xiong Xia's work include Head and Neck Cancer Studies (51 papers), Lung Cancer Treatments and Mutations (14 papers) and Head and Neck Surgical Oncology (11 papers). Wei‐Xiong Xia is often cited by papers focused on Head and Neck Cancer Studies (51 papers), Lung Cancer Treatments and Mutations (14 papers) and Head and Neck Surgical Oncology (11 papers). Wei‐Xiong Xia collaborates with scholars based in China, United States and Hong Kong. Wei‐Xiong Xia's co-authors include Yan‐Qun Xiang, Xing Lv, Xiang Guo, Hu L, Liang‐Ru Ke, Ya‐Hui Yu, Guoying Liu, Yan‐Fang Ye, Wang‐Zhong Li and Xiang Guo and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Wei‐Xiong Xia

63 papers receiving 903 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wei‐Xiong Xia China	19	430	408	216	208	188	65	912
Jingao Li China	18	408 0.9×	297 0.7×	196 0.9×	338 1.6×	329 1.8×	85	1.1k
Kenneth C.W. Wong Hong Kong	13	220 0.5×	297 0.7×	273 1.3×	154 0.7×	165 0.9×	44	889
Tseng‐Cheng Chen Taiwan	18	493 1.1×	361 0.9×	472 2.2×	243 1.2×	166 0.9×	67	1.0k
Wen‐Ze Qiu China	14	247 0.6×	227 0.6×	155 0.7×	135 0.6×	147 0.8×	34	578
Connie Chan China	9	494 1.1×	284 0.7×	291 1.3×	238 1.1×	135 0.7×	15	814
Song Qu China	19	419 1.0×	480 1.2×	262 1.2×	264 1.3×	313 1.7×	97	1.1k
Shaobo Liang China	19	802 1.9×	448 1.1×	526 2.4×	332 1.6×	197 1.0×	58	1.3k
Atsushi Motegi Japan	20	125 0.3×	272 0.7×	332 1.5×	495 2.4×	237 1.3×	75	1.1k
Jiyi Hu China	17	186 0.4×	188 0.5×	178 0.8×	271 1.3×	109 0.6×	52	670

Countries citing papers authored by Wei‐Xiong Xia

Since Specialization

Citations

This map shows the geographic impact of Wei‐Xiong Xia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei‐Xiong Xia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei‐Xiong Xia more than expected).

Fields of papers citing papers by Wei‐Xiong Xia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wei‐Xiong Xia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei‐Xiong Xia. The network helps show where Wei‐Xiong Xia may publish in the future.

Co-authorship network of co-authors of Wei‐Xiong Xia

This figure shows the co-authorship network connecting the top 25 collaborators of Wei‐Xiong Xia. A scholar is included among the top collaborators of Wei‐Xiong Xia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wei‐Xiong Xia. Wei‐Xiong Xia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Deng, Yishu, Yingying Huang, Haijun Wu, et al.. (2025). Establishment of a deep-learning-assisted recurrent nasopharyngeal carcinoma detecting simultaneous tactic (DARNDEST) with high cost-effectiveness based on magnetic resonance images: a multicenter study in an endemic area. Cancer Imaging. 25(1). 39–39.

Cao, Xun, Han-Ying Huang, Jiayu Zhou, et al.. (2025). Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial. Clinical Cancer Research. 31(15). 3133–3141. 1 indexed citations

Cao, Xun, Jiayu Zhou, Xi Chen, et al.. (2024). Toripalimab plus capecitabine in the treatment of patients with residual nasopharyngeal carcinoma: a single-arm phase 2 trial. Nature Communications. 15(1). 949–949. 5 indexed citations

Li, Wang‐Zhong, Ying Huang, Xiaobin Zhu, et al.. (2024). Single‐cell transcriptome analysis reveals evolving tumour microenvironment induced by immunochemotherapy in nasopharyngeal carcinoma. Clinical and Translational Medicine. 14(10). e70061–e70061. 2 indexed citations

Chen, Chun, Guoying Liu, Ting Fang, et al.. (2024). Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy. Scientific Reports. 14(1). 1768–1768. 2 indexed citations

Liu, Guoying, et al.. (2024). Efficacy and Safety of Re-Challenging PD-1 Inhibitors in Second-Line Treatment in Metastatic Nasopharyngeal Carcinoma Previously Treated with Chemotherapy and PD-1 Inhibitors. Cancer Management and Research. Volume 16. 771–780. 4 indexed citations

Li, Zhuo, et al.. (2023). Effective of metastasis‐directed therapy for de novo metastatic nasopharyngeal carcinoma: A propensity score matched analysis. Head & Neck. 45(10). 2571–2579. 1 indexed citations

Fang, Ting, et al.. (2023). Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients. Critical Reviews in Oncology/Hematology. 190. 104113–104113. 8 indexed citations

Huang, Yingying, Jiayu Zhou, Liang‐Ru Ke, et al.. (2023). Tumor residue in patients with stage II–IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein–Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose. BMC Cancer. 23(1). 410–410. 2 indexed citations

10.

Li, Wang‐Zhong, Shu‐Hui Lv, Guoying Liu, et al.. (2023). Epstein-Barr virus DNA seropositivity links distinct tumoral heterogeneity and immune landscape in nasopharyngeal carcinoma. Frontiers in Immunology. 14. 1124066–1124066.

11.

Liu, Guoying, Nian Lu, Wang‐Zhong Li, et al.. (2023). Development of a prognostic model to identify the metastatic nasopharyngeal carcinoma patients who may benefit from chemotherapy combination PD-1 inhibitor. Frontiers in Immunology. 14. 1069010–1069010. 3 indexed citations

12.

Wang, Lin, Nian Lu, Jianwei Wang, et al.. (2022). Efficacy and safety of camrelizumab and apatinib combined with induction chemotherapy and concurrent chemoradiotherapy for stage T _any N3M0 nasopharyngeal carcinoma: A phase II QUINTUPLED trial.. Journal of Clinical Oncology. 40(16_suppl). 6012–6012. 1 indexed citations

13.

Wang, Lin, Jingjing Miao, Boyu Chen, et al.. (2021). Long-term Survivals, Toxicities and the Role of Chemotherapy in Early-Stage Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiation Therapy: A Retrospective Study with 15-Year Follow-up. Cancer Research and Treatment. 54(1). 118–129. 18 indexed citations

14.

Li, Wang‐Zhong, Xin Hua, Shu‐Hui Lv, et al.. (2021). A Scoring System Based on Nutritional and Inflammatory Parameters to Predict the Efficacy of First-Line Chemotherapy and Survival Outcomes for De Novo Metastatic Nasopharyngeal Carcinoma. Journal of Inflammation Research. Volume 14. 817–828. 14 indexed citations

15.

Lv, Shu‐Hui, Wang‐Zhong Li, Hu L, et al.. (2021). Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy. Journal of Inflammation Research. Volume 14. 2225–2237. 5 indexed citations

16.

Li, Wang‐Zhong, Guoying Liu, Shu‐Hui Lv, et al.. (2020). MRI-detected residual retropharyngeal lymph node after intensity-modulated radiotherapy in nasopharyngeal carcinoma: Prognostic value and a nomogram for the pretherapy prediction of it. Radiotherapy and Oncology. 145. 101–108. 14 indexed citations

17.

Li, Shuai, et al.. (2018). Disrupting SOD1 activity inhibits cell growth and enhances lipid accumulation in nasopharyngeal carcinoma. Cell Communication and Signaling. 16(1). 28–28. 43 indexed citations

18.

Chan, Carmen W.H., Yuying Fan, Doris Y. P. Leung, et al.. (2017). Symptom clusters in patients with nasopharyngeal carcinoma during radiotherapy. European Journal of Oncology Nursing. 28. 7–13. 30 indexed citations

19.

Yu, Ya‐Hui, Wei‐Xiong Xia, Junli Shi, et al.. (2016). A model to predict the risk of lethal nasopharyngeal necrosis after re-irradiation with intensity-modulated radiotherapy in nasopharyngeal carcinoma patients. Chinese Journal of Cancer. 35(1). 59–59. 31 indexed citations

20.

Zhu, Yuliang, Qun Li, Zhen‐Yu He, et al.. (2013). Clinical Features and Treatment Response of Solid Neuroendocrine Breast Carcinoma to Adjuvant Chemotherapy and Endocrine Therapy. The Breast Journal. 19(4). 382–387. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact